Advertisement
Journal Home
Search for

Volume 34, Issue 11, Pages 1462-1470 (November 2006)


View previous. 4 of 24 View next.

DNA methylation during mouse hemopoietic differentiation and radiation-induced leukemia

George Giotopoulosa, Carol McCormickb, Clare Colea, Abigail Zankera, Mays Jawada, Robert Brownb, Mark PlumbaCorresponding Author Informationemail address

Received 30 March 2006; received in revised form 8 June 2006; accepted 13 June 2006.

Objective

To examine DNA methylation in mouse hemopoiesis before and after in vivo exposure to a leukemogenic dose of x-rays, and address whether methylation levels are associated with the relative radiosensitivity of tissues in vivo.

Methods

The methylation status of control CBA/H and C57BL/6 mouse tissues before and after exposure to 3-Gy x-rays, and myeloid and lymphoid leukemias and lymphomas, was assessed by the direct analysis of the 5-methylcytosine (5-MeC) content of DNA, and by Southern blot analysis of genomic repeat sequences.

Results

The DNA 5-MeC content of bone marrow is 15% lower than spleen. Together with the analyses of stem (myeloid) and progenitor (lymphoid) leukemias and lymphomas, we found a trend of increasing methylation during hemopoietic differentiation. Exposure to x-rays induced greater cell death in the hypomethylated bone marrow (>80%) than spleen (50%) in vivo, supporting the observed correlation found between methylation status and radiosensitivity of other high-turnover hierarchical tissues. Furthermore, there was an 8% DNA 5-MeC content decrease in bone marrow after in vivo exposure to 3-Gy x-rays, but this was genotype dependent, being observed in AML-susceptible (CBA/H) but not AML-resistant (C57BL/6) inbred mice.

Conclusion

Together these data suggest that methylation status may be related to the relative radiosensitivity of high-turnover hierarchical tissues such as bone marrow and that radiation-induced DNA hypomethylation has a role in radiation leukemogenesis.

a Department of Genetics, University of Leicester, Leicester, United Kingdom

b Centre for Oncology & Applied Pharmacology, CRUK Beatson Laboratories, Glasgow University, Glasgow, United Kingdom

Corresponding Author InformationOffprint requests to: Mark Plumb, B.Sc., Ph.D., Department of Genetics, University of Leicester, University Road, Leicester LE1 7RH, UK

PII: S0301-472X(06)00395-X

doi:10.1016/j.exphem.2006.06.008


View previous. 4 of 24 View next.